Blog

Katy Beckermann: Secondary Analysis of the TITAN Trial

Katy Beckermann/medschool.vanderbilt.edu

Apr 1, 2025, 04:49

Katy Beckermann: Secondary Analysis of the TITAN Trial

Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, posted on X:

“New analysis from the TITAN trial:

In mCSPC patients treated with apalutamide:

Discordant progression occurred in 52.2% of patients (60 of 115) in the apalutamide group and 27.5% (58 of 211) in the placebo group (p < 0.001).

Takeaway: PSA alone isn’t enough—routine imaging is critical!”

“Radiographic Progression Without Corresponding Prostate-specific Antigen Progression in Patients with Metastatic Castration-sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial.”

Authors: Wataru Fukuokaya, Takafumi Yanagisawa, Keiichiro Mori, Fumihiko Urabe, Pawel Rajwa, Alberto Briganti, Shahrokh F. Shariat, Takahiro Kimura

Katy Beckermann

Alberto Briganti cancer Fumihiko Urabe Katy Beckermann Keiichiro Mori OncoDaily Oncology Pawel Rajwa prostate cancer Shahrokh F Shariat Takafumi Yanagisawa Takahiro Kimura TITAN trial Wataru Fukuokaya

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

Highlights from ELCC 2025

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

Meet the New AACR Board of Directores for 2025-2028 Term

Do Artificial Sweeteners Cause Cancer? Myths and Facts